A. van Pel

发表

Tumor antigens recognized by T lymphocytes.

P. Bruggen, T. Boon, J. Cerottini, 1994, Annual review of immunology.

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

Catia, P. Chomez, T. Boon, 1992, The Journal of experimental medicine.

Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.

P. Coulie, F. Brasseur, T. Boon, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Tum- transplantation antigens, point mutations, and antigenic peptides: a model for tumor-specific transplantation antigens?

T. Boon, E. De Plaen, A. van Pel, 1989, Cancer cells.

Production of stable cytolytic T‐cell clones directed against autologous human melanoma

R. Devos, T. Boon, M. Hérin, 1987, International journal of cancer.

Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression.

P. Chomez, T. Boon, B. Mariamé, 1989, Cold Spring Harbor symposia on quantitative biology.

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.

J. Renauld, P. Coulie, P. Bruggen, 1997, Methods.

A tyrosinase peptide presented by HLA‐B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes

T. Wölfel, P. van der Bruggen, B. J. Van den Eynde, 1999, International journal of cancer.

Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.

F. Brasseur, P. Bruggen, T. Boon, 1999, Journal of immunology.

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

J. Shabanowitz, D. Hunt, V. Engelhard, 1996, The Journal of experimental medicine.

Use of a skin test assay to determine tumor‐specific CD8+ T cell reactivity

C. Uyttenhove, U. Grohmann, P. Puccetti, 1994, European journal of immunology.

Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide

T. Boon, B. J. Van den Eynde, A. van Pel, 1992, European journal of immunology.

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis

C. Uyttenhove, T. Boon, J. Snick, 1980, The Journal of experimental medicine.

The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides.

F. Salemme, P. Romero, T. Boon, 1991, International immunology.

The tum− antigens P91A and P198 derive from proteins located in the cytosolic compartment of cells

A. Dautry‐Varsat, A. van Pel, A. Amar‐Costesec, 1993, European journal of immunology.

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

P. Romero, D. Valmori, F. Jotereau, 1997, Journal of immunology.

Specific lysis of murine cells expressing HLA molecules by allospecific human and murine H‐2‐restricted anti‐HLA T killer lymphocytes

J. Levy, A. van Pel, P. Paul, 1986, European journal of immunology.

Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815

T. Boon, S. Lucas, A. van Pel, 1995, European journal of immunology.

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

B. Neyns, F. Brasseur, T. Boon, 2007, Cancer Immunology, Immunotherapy.

Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.

J. Renauld, T. Boon, A. van Pel, 1995, Journal of immunology.

Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells1

B. Neyns, F. Brasseur, T. Boon, 2008, The Journal of Immunology.

CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation.

T. Boon, P. van der Bruggen, A. van Pel, 2006, Blood.

Human T cell recognition of cloned HL A class I gene products expressed on DNA transfectants of mouse mastocytoma P815

T. Boon, B. Jordan, A. Moretta, 1985, European journal of immunology.

Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis

T. Boon, A. van Pel, F. Vessiere, 1983, The Journal of experimental medicine.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

P. Coulie, T. Connerotte, T. Boon, 2002, Immunological reviews.

Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1

P. Coulie, G. Schuler, T. Boon, 2003, The Journal of Immunology.

Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.

T. Boon, A. van Pel, A. Pel, 1978, Proceedings of the National Academy of Sciences of the United States of America.

Identification of tumour rejection antigens recognized by T lymphocytes.

T. Boon, P. van der Bruggen, C. Traversari, 1992, Cancer surveys.

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H‐2 associativity of variant‐specific antigens

J. Van Snick, G. Parmiani, A. van Pel, 1982, European journal of immunology.

Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes

M. Perricaudet, C. Uyttenhove, T. Boon, 2001, Cancer Immunology, Immunotherapy.

Antigens recognized by T-lymphocytes on human tumours.

P. Coulie, T. Boon, P. van der Bruggen, 1997, Biochemical Society transactions.

CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum− or helper peptides in priming for skin test reactivity to a P815AB‐related peptide

C. Uyttenhove, U. Grohmann, P. Puccetti, 1995, European journal of immunology.

Cloning and characterization of genes coding for tum- transplantation antigens.

T. Boon, T. Wölfel, A. van Pel, 1989, Journal of autoimmunity.

Immunogenic variants obtained by mutagenesis of mouse Lewis lung carcinoma. Recognition of variant-specific antigens by cytolytic T lymphocytes.

T. Boon, A. van Pel, J. Leclerc, 1982, European journal of cancer & clinical oncology.

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

P. Coulie, T. Boon, T. Wölfel, 1993, The Journal of experimental medicine.

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

J. Renauld, P. Coulie, T. Boon, 1994, The Journal of experimental medicine.

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene

F. Brasseur, C. Viret, T. Boon, 1996, The Journal of experimental medicine.

An intracisternal A‐particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia

P. Chomez, T. Boon, A. van Pel, 1994, European journal of immunology.

Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide

P. Chomez, T. Boon, A. van Pel, 1990, The Journal of experimental medicine.

The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

T. Boon, B. J. Van den Eynde, A. van Pel, 1991, The Journal of experimental medicine.

Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.

E. Tartour, P. Coulie, T. Connerotte, 2008, Cancer research.

Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes

B. Seliger, T. Boon, T. Wölfel, 1994, European journal of immunology.

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

P. Chomez, T. Boon, T. Wölfel, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.

T. Boon, A. van Pel, A. Van, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Stimulation of cytolytic T lymphocytes by azaguanine-resistant mouse tumor cells in selective HAT medium.

C. Uyttenhove, T. Boon, J. Van Snick, 1981, Journal of immunological methods.

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen

P. Coulie, T. Connerotte, T. Boon, 2004, Proceedings of the National Academy of Sciences of the United States of America.

A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

T. Boon, T. Wölfel, A. van Pel, 1996, European journal of immunology.

Cytolytic T‐cell responses of cancer patients vaccinated with a MAGE antigen

P. Coulie, T. Connerotte, T. Boon, 2002 .

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1

P. Rod Dunbar, Vincenzo Cerundolo, V. Cerundolo, 2002, The Journal of Immunology.

Transporter (TAP)‐ and proteasome‐independent presentation of a melanoma‐associated tyrosinase epitope

C. Huber, G. Sutter, T. Wölfel, 2000, International journal of cancer.

Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.

C. Uyttenhove, T. Boon, B. J. Van den Eynde, 1999, Journal of immunology.

Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant.

H. Rammensee, T. Boon, H. Wallny, 1992, International immunology.

Structure of the gene of tum‐ transplantation antigen P35B: presence of a point mutation in the antigenic allele.

T. Boon, N. van Baren, A. van Pel, 1990, The EMBO journal.

Host-controlled restriction mutants of Salmonella typhimurium.

C. Colson, A. van Pel, A. Colson, 1969, Journal of General Microbiology.

Chromosomal location of host specificity in Salmonella typhimurium.

C. Colson, A. van Pel, A. Colson, 1970, Journal of general microbiology.

Presentation of mouse tum− P91A antigen from chimeric proteins with different subcellular localizations by class I molecules of the major histocompatibility complex

A. van Pel, D. Godelaine, H. Beaufay, 1993, European journal of immunology.

Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice.

T. Boon, A. van Pel, M. Georlette, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.

E. Tartour, P. Coulie, T. Connerotte, 2008, Cancer Research.